Journal
CIRCULATION
Volume 101, Issue 2, Pages 207-213Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.CIR.101.2.207
Keywords
statins; hypercholesterolemia; trials; atherosclerosis; coronary disease
Funding
- NHLBI NIH HHS [HL-53989, HL-57986] Funding Source: Medline
Ask authors/readers for more resources
Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of hypercholesterolemia. They inhibit HMG-CoA reductase competitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride levels in hypertriglyceridemic patients. Statins are well tolerated and have an excellent safety record. Clinical trials in patients with and without coronary heart disease and with and without high cholesterol have demonstrated consistently that statins reduce the-relative risk of major coronary events by approximate to 30% and produce a greater absolute benefit in patients with higher baseline risk. Proposed mechanisms include favorable effects on plasma lipoproteins, endothelial function, plaque architecture and stability, thrombosis, and inflammation. Mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may ultimately broaden their indication from lipid-lowering to antiatherogenic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available